Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Captrust Financial Advisors

Captrust Financial Advisors boosted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 129.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,428 shares of the biopharmaceutical company’s stock after acquiring an additional 6,445 shares during the quarter. Captrust Financial Advisors’ holdings in Ultragenyx Pharmaceutical were worth $635,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. nVerses Capital LLC acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $33,000. UMB Bank n.a. boosted its stake in shares of Ultragenyx Pharmaceutical by 58.1% during the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 352 shares during the last quarter. Values First Advisors Inc. acquired a new position in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $56,000. Capital Performance Advisors LLP purchased a new position in shares of Ultragenyx Pharmaceutical during the third quarter valued at approximately $107,000. Finally, Quest Partners LLC acquired a new stake in Ultragenyx Pharmaceutical during the third quarter worth approximately $119,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on RARE shares. HC Wainwright increased their price target on Ultragenyx Pharmaceutical from $82.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. TD Cowen lifted their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a report on Monday, October 21st. Royal Bank of Canada reiterated an “outperform” rating and set a $77.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a research note on Thursday, November 21st. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $87.46.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the business’s stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the sale, the chief financial officer now owns 92,301 shares of the company’s stock, valued at $4,869,800.76. The trade was a 7.48 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Emil D. Kakkis sold 8,273 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.00, for a total value of $413,650.00. Following the completion of the sale, the chief executive officer now directly owns 2,195,712 shares in the company, valued at approximately $109,785,600. This represents a 0.38 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 0.5 %

Shares of RARE stock opened at $48.86 on Thursday. The business has a 50 day moving average of $50.77 and a two-hundred day moving average of $49.06. The company has a market cap of $4.51 billion, a P/E ratio of -7.55 and a beta of 0.56. Ultragenyx Pharmaceutical Inc. has a 52 week low of $37.02 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The firm had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. During the same quarter in the prior year, the firm earned ($2.23) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 42.3% on a year-over-year basis. Analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.